The importance of examining the proportion of circulating DNA originating from tumor, microenvironment and normal cells in colorectal cancer patients
- PMID: 22594497
- DOI: 10.1517/14712598.2012.688023
The importance of examining the proportion of circulating DNA originating from tumor, microenvironment and normal cells in colorectal cancer patients
Abstract
Introduction: The pressing need to determine the KRAS/BRAF mutational status for selecting patients with colorectal cancer (CRC) for anti-EGFR therapy provides a great opportunity to use circulating DNA (ctDNA) as a theranostic tool for personalized medicine. Better understanding of ctDNA origin (necrosis, apoptosis and active release) may increase the reliability of using abnormal ctDNA as biomarker.
Areas covered: The authors showed that examining the proportion of ctDNA originating from tumor, microenvironment and normal cells, through size distribution and mutation load may help to discriminate mechanisms of ctDNA release.
Expert opinion: Contrary to the literature, it was observed that tumor-derived ctDNA was mostly shorter than 100 bp. Tumor-derived ctDNA from cancer patients exhibited a specific ctDNA size distribution profile and significantly higher ctDNA fragmentation than ctDNA from healthy individuals. Examination of the KRAS and BRAF mutational load in 48 mutated samples revealed very high variation ranging from 0.037 to 68.8%. This suggests either that tumor cells variably release ctDNA compared with tumor-associated stroma cells or normal cells, or that mutant ctDNA analysis may depend on tumor clonality. Detection of point mutation by quantifying the proportion of mutant ctDNA fragments provides a powerful tool for assessing the proportion of ctDNA from different origins.
Similar articles
-
Clinical utility of circulating DNA analysis for rapid detection of actionable mutations to select metastatic colorectal patients for anti-EGFR treatment.Ann Oncol. 2017 Sep 1;28(9):2149-2159. doi: 10.1093/annonc/mdx330. Ann Oncol. 2017. PMID: 28911069
-
Origin and quantification of circulating DNA in mice with human colorectal cancer xenografts.Nucleic Acids Res. 2010 Oct;38(18):6159-75. doi: 10.1093/nar/gkq421. Epub 2010 May 21. Nucleic Acids Res. 2010. PMID: 20494973 Free PMC article.
-
Concordance in KRAS and BRAF mutations in endoscopic biopsy samples and resection specimens of colorectal adenocarcinoma.Eur J Cancer. 2012 May;48(7):1108-15. doi: 10.1016/j.ejca.2012.02.054. Epub 2012 Mar 23. Eur J Cancer. 2012. PMID: 22446020
-
BRAF provides proliferation and survival signals in MSI colorectal carcinoma cells displaying BRAF(V600E) but not KRAS mutations.J Pathol. 2008 Feb;214(3):320-7. doi: 10.1002/path.2295. J Pathol. 2008. PMID: 18098337
-
Carrier molecules and extraction of circulating tumor DNA for next generation sequencing in colorectal cancer.Acta Medica (Hradec Kralove). 2016;59(2):54-8. doi: 10.14712/18059694.2016.54. Acta Medica (Hradec Kralove). 2016. PMID: 27526306
Cited by
-
Protocol Outlines for Parts 1 and 2 of the Prospective Endoscopy III Study for the Early Detection of Colorectal Cancer: Validation of a Concept Based on Blood Biomarkers.JMIR Res Protoc. 2016 Sep 13;5(3):e182. doi: 10.2196/resprot.6346. JMIR Res Protoc. 2016. PMID: 27624815 Free PMC article.
-
DNA studies using atomic force microscopy: capabilities for measurement of short DNA fragments.Front Mol Biosci. 2015 Jan 29;2:1. doi: 10.3389/fmolb.2015.00001. eCollection 2015. Front Mol Biosci. 2015. PMID: 25988169 Free PMC article. Review.
-
Oncogene addiction and tumor mutational burden in non-small-cell lung cancer: Clinical significance and limitations.Thorac Cancer. 2020 Feb;11(2):205-215. doi: 10.1111/1759-7714.13246. Epub 2019 Dec 4. Thorac Cancer. 2020. PMID: 31799812 Free PMC article. Review.
-
Origins, structures, and functions of circulating DNA in oncology.Cancer Metastasis Rev. 2016 Sep;35(3):347-76. doi: 10.1007/s10555-016-9629-x. Cancer Metastasis Rev. 2016. PMID: 27392603 Free PMC article. Review.
-
Circulating Cell-Free Nucleic Acids: Main Characteristics and Clinical Application.Int J Mol Sci. 2020 Sep 17;21(18):6827. doi: 10.3390/ijms21186827. Int J Mol Sci. 2020. PMID: 32957662 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous
